Imatinib Mesylate for Children With Dermatofibrosarcoma Protuberans (DFSP)

被引：40

作者：

Gooskens, Saskia L. M. ^{[1
]}

Oranje, Arnold P. ^{[2
]}

van Adrichem, Leon N. A. ^{[3
]}

de Waard-van der Spek, Flora B. ^{[2
]}

den Hollander, Jan C. ^{[4
]}

van de Ven, Cees P. ^{[5
]}

van den Heuvel-Eibrink, Marry M. ^{[1
]}

机构：

[1] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands

[2] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Dermatol, NL-3015 GJ Rotterdam, Netherlands

[3] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Plast Surg, NL-3015 GJ Rotterdam, Netherlands

[4] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pathol, NL-3015 GJ Rotterdam, Netherlands

[5] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Surg, NL-3015 GJ Rotterdam, Netherlands

来源：

PEDIATRIC BLOOD & CANCER | 2010年 / 55卷 / 02期

关键词：

children; dermatofibrosarcoma protuberans; imatinib; treatment; CHILDHOOD; TUMORS;

D O I：

10.1002/pbc.22494

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet-derived growth factor beta (POGF beta) with the collagen type 1 alpha 1 (COL 1 alpha 1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome. Pediatr Blood Cancer 2010;55:369-373. (C) 2010 Wiley-Liss, Inc.

引用

页码：369 / 373

页数：5

共 50 条

[41] Dermatofibrosarcoma Protuberans
Acosta, Alvaro E.
Santa Velez, Catalina
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (09)
[42] Dermatofibrosarcoma protuberans: Our experience of 59 cases
Stivala, Alessio
Lombardo, Giuseppe A. G.
Pompili, Gianluca
Tarico, Maria Stella
Fraggetta, Filippo
Perrotta, Rosario Emanuele
ONCOLOGY LETTERS, 2012, 4 (05) : 1047 - 1055
[43] Dermatofibrosarcoma protuberans
Mendenhall, WM
Zlotecki, RA
Scarborough, MT
CANCER, 2004, 101 (11) : 2503 - 2508
[44] Dermatofibrosarcoma Protuberans
Allen, Aubrey
Ahn, Christine
Sangueza, Omar P.
DERMATOLOGIC CLINICS, 2019, 37 (04) : 483 - +
[45] Dermatofibrosarcoma Protuberans
Alvaro E. Acosta
Catalina Santa Vélez
Current Treatment Options in Oncology, 2017, 18
[46] Dermatofibrosarcoma Protuberans
LeBlanc, Jessica
Chan, Conner
Zedlitz, Ann
CUTIS, 2017, 100 (01): : E6 - E7
[47] Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line
Ono, Takuya
Noguchi, Rei
Osaki, Julia
Akiyama, Taro
Adachi, Yuki
Kojima, Naoki
Toda, Yu
Fukushima, Suguru
Yoshimatsu, Yuki
Yoshida, Akihiko
Kawai, Akira
Kondo, Tadashi
HUMAN CELL, 2024, 37 (03) : 854 - 864
[48] Imaging features of dermatofibrosarcoma protuberans
Ren, Qingguo
Li, Jiuwen
Shangguan, Jingjun
Feng, Xiushuan
Ma, Xiangxing
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (02) : 476 - 481
[49] Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line
Yoshimatsu, Yuki
Noguchi, Rei
Tsuchiya, Ryuto
Sei, Akane
Nakagawa, Makoto
Yoshida, Akihiko
Kawai, Akira
Kondo, Tadashi
HUMAN CELL, 2020, 33 (03) : 894 - 903
[50] DERMATOFIBROSARCOMA PROTUBERANS - TREATMENT AND PROGNOSIS
RUTGERS, EJT
KROON, BBR
ALBUSLUTTER, CE
GORTZAK, E
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1992, 18 (03): : 241 - 248

← 1 2 3 4 5 →